DeepMed Research

Zhejiang Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.zchospital.com

Clinical Trials

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

Conditions: Breast Cancer

First Posted Date: 2021-09-01

Last Posted Date: 2022-03-02

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 50

Registration Number: NCT05030519

Locations: 🇨🇳
China, Zhejiang, Hangzhou, China

Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC

Early Phase 1

Conditions: Hepatocellular Carcinoma Stage IIIa

Interventions: Drug: Lenvatinib
Drug: mFOLFOX regimen
Drug: ROX regimen

First Posted Date: 2021-08-16

Last Posted Date: 2021-08-16

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT05007587

Locations: 🇨🇳
The Cancer Hospital of the University of Chinese Academy of Sciences（Zhejiang Cancer Hospital）, Hangzhou, Zhejiang, China

Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer

Phase 3

Recruiting

Conditions: Cervical Cancer

Interventions: Radiation: Pelvic definitive concurrent chemoradiation
Radiation: Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation

First Posted Date: 2021-07-23

Last Posted Date: 2022-01-25

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 455

Registration Number: NCT04974346

Locations: 🇨🇳
Lishui People's Hospital, Lishui, China
🇨🇳
Chongqing University Three Gorges Hospital, Wanzhou, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

and more 4 locations

RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer

Not yet recruiting

Conditions: Recurrence
Breast Cancer

First Posted Date: 2021-07-22

Last Posted Date: 2021-07-22

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 500

Registration Number: NCT04972448

A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

Phase 2

Conditions: Small Cell Lung Cancer Extensive Stage

Interventions: Drug: Sintilimab
Drug: Anlotinib hydrochloride

First Posted Date: 2021-07-19

Last Posted Date: 2021-07-28

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 23

Registration Number: NCT04967625

HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis

Not Applicable

Not yet recruiting

Conditions: Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery

Interventions: Drug: HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery

First Posted Date: 2021-05-17

Last Posted Date: 2021-05-17

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 46

Registration Number: NCT04889768

Locations: 🇨🇳
The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China

A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma

Phase 2

Conditions: Chemotherapy Effect
Gray Zone Lymphoma
Relapse/Recurrence

Interventions: Drug: PD-1 inhibitor +ICE

First Posted Date: 2021-04-27

Last Posted Date: 2021-04-27

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT04860674

Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients

Phase 2

Conditions: Breast Neoplasms

Interventions: Drug: Palbociclib
Drug: AI

First Posted Date: 2021-04-26

Last Posted Date: 2021-07-15

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 150

Registration Number: NCT04858997

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

Phase 2

Active, not recruiting

Conditions: Lung Cancer

Interventions: Drug: Almonertinib

First Posted Date: 2021-03-22

Last Posted Date: 2024-04-22

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 63

Registration Number: NCT04808752

Locations: 🇨🇳
Cancer Hospital Affiliated to University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China

Establishment of Tongue Image Database and Machine Learning Model for Malignant Tumors Diagnosis

Completed

Conditions: Malignant Tumor

Interventions: Other: Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.

First Posted Date: 2021-03-11

Last Posted Date: 2024-07-30

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 4100

Registration Number: NCT04793672

Locations: 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy